4.8 Article

Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes

Journal

CELL REPORTS
Volume 37, Issue 1, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2021.109793

Keywords

-

Categories

Funding

  1. National Key R&D Program of China [2020YFA0112200]
  2. National Natural Science Foundation of China [91940306, T2125012, 31970858, 31771428, 31700796, 81871479]
  3. CAS Project for Young Scientists in Basic Research [YSBR-005]
  4. Fundamental Research Funds for the Central Universities [YD2070002019, WK9110000141, WK2070000158, WK9100000001]

Ask authors/readers for more resources

The study reveals the inflammatory characteristics of peripheral blood mononuclear cells in COVID-19 patients through single-cell transcriptomic analysis, and identifies shared inflammatory characteristics with HIV infection and sepsis.
The mortality risk of coronavirus disease 2019 (COVID-19) patients has been linked to the cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding the inflammatory responses shared between COVID-19 and other infectious diseases that feature cytokine storms may therefore help in developing improved therapeutic strategies. Here, we use integrative analysis of single-cell transcriptomes to characterize the inflammatory signatures of peripheral blood mononuclear cells from patients with COVID-19, sepsis, and HIV infection. We identify ten hyperinflammatory cell subtypes in which monocytes are the main contributors to the transcriptional differences in these infections. Monocytes from COVID-19 patients share hyperinflammatory signatures with HIV infection and immunosuppressive signatures with sepsis. Finally, we construct a three-stage'' model of heterogeneity among COVID-19 patients, related to the hyperinflammatory and immunosuppressive signatures in monocytes. Our study thus reveals cellular and molecular insights about inflammatory responses to SARS-CoV-2 infection and provides therapeutic guidance to improve treatments for subsets of COVID-19 patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available